🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Amyloidosis; Systemic

BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis NCT07151690Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: anti-BCMA/CD3 bispecific antibody Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis NCT06022939Phase 3117 sites📍 Goodyear📍 Tucson📍 Tucson SWOG Cancer Research Network · Tests: Autologous Hematopoietic Stem Cell Transplantation, Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow… Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: biologic sample preservation procedure, cytology specimen collection procedure Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research NCT07085559EARLY Phase 11 site📍 Hefei Anhui Provincial Hospital · Tests: Metabolically Armed BCMA CAR-T cells. Teclistamab in Previously Treated AL Amyloidosis NCT06935162Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Teclistamab (Tec) DapagliFLOzin in Renal AL Amyloidosis (FLORAL) NCT06420167Phase 21 site📍 Detroit Barbara Ann Karmanos Cancer Institute · Tests: Dapagliflozin Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis NCT06699394NA2 sites📍 Beijing📍 Beijing Peking University People's Hospital · Tests: Teclistamab (Tec) Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients NCT07266116Phase 1, Phase 227 sites📍 Beijing📍 Beijing📍 Chongqing Shanghai Chia Tai Tianqing Pharmaceutical Technology Develo… · Tests: TQB2934 injection A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). NCT07638683Phase 21 site📍 Shanghai Shanghai Zhongshan Hospital · Tests: Teclistamab Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment NCT07448779n/a1 site📍 Pavia Fondazione IRCCS Policlinico San Matteo di Pavia Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial NCT05898646Phase 22 sites📍 Scottsdale📍 Rochester Mayo Clinic · Tests: Bone Marrow Aspiration, Daratumumab, Echocardiography Test, Questionnaire Administration, X-Ray Imaging A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA) NCT06205953n/a6 sites📍 Heidelberg📍 Pavia📍 Utrecht Fondazione IRCCS Policlinico San Matteo di Pavia Observational Epidemiological Study of Patients Suffering From Systemic Amyloidosis NCT06866912n/a1 site📍 Bologna IRCCS Azienda Ospedaliero-Universitaria di Bologna Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource NCT01408225n/a1 site📍 Columbus Ohio State University Comprehensive Cancer Center · Tests: tissue banking SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders NCT07850284n/a1 site📍 Rochester Mayo Clinic · Tests: Non-Interventional Study The Italian Transthyretin Amyloidosis Web-Network NCT05444920n/a30 sites📍 Legnano📍 Orbassano📍 Ancona Fondazione IRCCS Policlinico San Matteo di Pavia Rapid dFLC Response Predict CHR in AL Amyloidosis NCT06627309n/a8 sites📍 Beijing📍 Beijing📍 Beijing Peking University People's Hospital · Tests: Dara IV, Bortezomib (drug), Dexamethasone, Cyclophosphamide (CTX), Dara SC BE.Amycon Biobank & Data Registry UZ Leuven NCT07172243n/a2 sites📍 Leuven📍 Leuven Universitaire Ziekenhuizen KU Leuven Daratumumab for Patients With Light Chain Amyloidosis NCT06376214NA1 site📍 Nanjing Nanjing University School of Medicine · Tests: Dratumumab / Hyaluronidase Injection [Darzalex Faspro], Pomalidomide 4 MG, autologous stem cell transplantation (ASCT) Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis NCT07079423Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Teclistamab (Tec) Optimize First-line Treatment for AL Amyloidosis With t (11; 14) NCT06192979NA7 sites📍 Beijing📍 Beijing📍 Beijing Jin Lu, MD · Tests: Daratumumab, Bortezomib, Dexamethasone, Venetoclax [18F]FT8 PET Imaging in Immunoglobulin Light Chain Amyloidosis NCT07232459n/a3 sites📍 Hefei📍 Qingdao📍 Tianjin Tianjin Medical University · Tests: [18F]FT8 Registry of Older Patients With Cancer NCT01137825n/a7 sites📍 Boone📍 Chapel Hill📍 Greenville UNC Lineberger Comprehensive Cancer Center Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis NCT07250269Phase 19 sites📍 Beijing📍 Beijing📍 Beijing Gracell Biotechnologies (Shanghai) Co., Ltd. · Tests: GC012F Injection Clinical Study for AL-CM NCT04924998n/a1 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: current treatment of AL-CM One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS NCT07448935n/a1 site📍 Pavia Fondazione IRCCS Policlinico San Matteo di Pavia A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. NCT07081646Phase 1, Phase 218 sites📍 Phoenix📍 San Francisco📍 Tampa Alexion Pharmaceuticals, Inc. · Tests: AZD0120 A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion NCT06158854Phase 1, Phase 223 sites📍 Miami📍 Boston📍 Rochester AbbVie · Tests: ABBV-383 (Etentamig) Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis NCT06569147Phase 1, Phase 25 sites📍 New Haven📍 Boston📍 Boston Dana-Farber Cancer Institute · Tests: Elranatamab Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis NCT05145816Phase 1, Phase 23 sites📍 Nashville📍 Dallas📍 Salt Lake City University of Texas Southwestern Medical Center · Tests: Belantamab mafodotin 2.5 mg/kg (8 weeks), Belantamab mafodotin 1.9 mg/kg (8 weeks), Belantamab mafodotin 1.4 mg/kg (12 …
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy